Activites

• 2003/10/14 Final act published in Official Journal
  • Directive 2003/74
  • OJ L 262 14.10.2003, p. 0017-0021
• 2003/09/22 Final act signed
• 2003/09/22 End of procedure in Parliament
• #2524
• 2003/07/22 Council Meeting
• 2003/07/02 Decision by Parliament, 2nd reading
  • T5-0317/2003 summary

    The European Parliament adopted some of the amendments in the report by Karl Erik OLSSEN (ELDR, Sweden). The amendments were designed to phase out the use of oestradiol 17 for oestrus induction over three years. However, the use of oestradiol for the treatment of certain conditions (foetus maceration or mummification or pyrometra in cattle) is maintained under strict conditions.�

• 2003/07/01 Debate in Parliament
  • Debate in Parliament
• 2003/05/22 Vote in committee, 2nd reading
  • A5-0201/2003
• 2003/03/13 Committee referral announced in Parliament, 2nd reading
• #2486
• 2003/02/20 Council Meeting
  • 14502/1/2002 summary

    The common position, adopted with the abstention of the United Kingdom, is based on a modified Commission proposal that already includes several amendments proposed by then European Parliament into account. As adopted by the Council by qualified majority, it does not alter the basic objectives of the proposed Directive: to protect consumer health and reach WTO compliance. There is no difference of opinion between the Council, the European Parliament and the Commission regarding the essential elements of the proposed directive and in particular on the need for maintaining a prohibition on the use of oestradiol 17 beta and its ester-like derivatives for growth promotion purposes and to introduce a temporary precautionary prohibition on the use of other hormones while additional scientific information, necessary for a fuller assessment of the risk, is gathered. In deciding such measures the Council has taken into account the latest scientific evidence and risk assessments, in particular the opinion of the SCVMPH of April 2002, together with other possible consequences, in particular environmental, of the large scale use of hormones in stock farming. The recitals of the proposed directive have been modified accordingly. Contrary to the Commission's proposal, the Council considered preferable to let the Parliament and the Council take future risk management decisions concerning the updates of the directive's provisions in the light of the new evidence which the Commission is required to gather taking into account recent scientific data from all possible sources and present to them. The Council, in agreement with the Commission and Parliament, has decided to maintain the use of certain of the substances, where this is strictly necessary, for therapeutic purposes or zootechnical treatment as this is not likely to constitute an unacceptable hazard for public health due to the nature and the limited duration of the treatments, the limited quantities administered and the strict conditions under which their administration can take place, laid down in Directive 96/22/EC in order to prevent any possible misuse. The Council has, however, considered appropriate, in the light of the existing information to limit as far as reasonably achievable the exposure to oestradiol 17 beta and only authorise those very few treatments (foetus maceration or mummification, pyometra in cattle and oestrus induction in cattle, horses, sheep or goats) for which no viable and effective alternatives seem presently to be available. Such treatments are not likely to present an unacceptable risk to public health, especially in the light of the new very stringent conditions required to be taken to avoid any possible abusive use. The Council has equally provided for a timely review of the provisions concerning treatments of farm animals with oestradiol 17 beta. Lastly, the Council feels that the fact that it has to a very large extent taken account of the European Parliament's position ought to lead to an early adoption of the Directive. There are also some statements added to this text, such as : - the Council and the Commission emphasise that the aim pursued in Article 11a is, in five years' time, to ban the use of oestradiol 17 beta or its ester-like derivatives for treating farm animals and replace it with equally effective substances; - the Commission undertakes to continue its efforts to establish Community-wide harmonised maximum levels for natural sex hormonesand validated methods of analysis, having due regard to physiological levels observed in farm animals.�

• #2476
• 2002/12/16 Council Meeting
• #X017
• 2002/09/23 Council Meeting
• #X016
• 2002/01/21 Council Meeting
• 2001/03/06 Modified legislative proposal published
  • COM(2001)0131 summary

    The amended proposal includes clarifications proposed by the European Parliament as regards wording in Article 1 (4) and Article 1 (7), in particular to the effect that the Commission will take into account recent scientific data from any source when keeping the measures under review.�

  • DG [{'url': 'http://ec.europa.eu/dgs/health_consumer/index_en.htm', 'title': 'Health and Consumers'}],
• 2001/02/01 Debate in Parliament
  • Debate in Parliament
  • T5-0051/2001 summary

    The European Parliament adopted the report by Mr Karl Erik Olsson (ELDR, S). Several amendments were adopted, one of which is designed to strengthen the monitoring of imports from third countries. (Please refer to the previous text).�

• 2001/01/09 Vote in committee, 1st reading/single reading
  • A5-0002/2001
• 2000/07/07 Committee referral announced in Parliament, 1st reading/single reading
• 2000/05/24 Legislative proposal published
  • COM(2000)0320 summary

    PURPOSE : to amend Council directive 96/22/EC regarding the use in stockfarming of certain hormonal substances. CONTENT : in the light of an opinion of the Scientific Committee on Veterninary measures relating to Public Health (SCVPH), the Commission proposes definitively to ban the use of oestradiol 17 beta and its ester-like derivatives in farm animals and to only allow its adminisatration to non-farm animals for therapeutic purposes. The administration of five other hormonal substances for animal growth promotion purposes is prohibited by the above directive. These are testosterone, progesterone, trenbolone acetate, zeranol and melengestrol acetate. In the case of these five, the need for further information ahs been identified. Therefore, the Commission proposes to continue provisionally to apply the prohibition on these five hormones until more complete scientific information is made available. The use of some of these substances may, however, continue to be authorised for therapeutical purposes and zootechnical treatment under the conditions of Council directive 96/22/EC. In comparison to the present situation, this proposal has an impact on imports from third countries who legally use oestradiol 17 beta and its ester-like derivatives for therapeutical purposes or zootechnical treatment in farm animals. The Commission considers the presentation of this proposal represents another step towards the implementation of the European Community's international obligations, specifically in the World Trade Organisation.�

  • DG [{'url': 'http://ec.europa.eu/dgs/health_consumer/index_en.htm', 'title': 'Health and Consumers'}],

Documents

• Legislative proposal published: COM(2000)0320
• Committee report tabled for plenary, 1st reading/single reading: A5-0002/2001
• Debate in Parliament: Debate in Parliament
• Decision by Parliament, 1st reading/single reading: T5-0051/2001
• Modified legislative proposal published: COM(2001)0131
• Council position published: 14502/1/2002
• Committee recommendation tabled for plenary, 2nd reading: A5-0201/2003
• Debate in Parliament: Debate in Parliament
• Decision by Parliament, 2nd reading: T5-0317/2003
• : Directive 2003/74
• : OJ L 262 14.10.2003, p. 0017-0021

History

(these mark the time of scraping, not the official date of the change)